Greenwich Book Value per Share Trend from 2010 to 2022

GLSI
 Stock
  

USD 9.60  0.10  1.03%   

Greenwich Lifesciences Book Value per Share is increasing over the last several years with slightly volatile swings. Book Value per Share is estimated to finish at 2.24 this year. During the period from 2010 to 2022 Greenwich Lifesciences Book Value per Share regressed destribution of quarterly values had coefficient of variationof(72.80) and r-value of  0.80. The current Consolidated Income is estimated to decrease to about (4.9 M). The current Earning Before Interest and Taxes EBIT is estimated to decrease to about (4.9 M).
  
Check Greenwich Lifesciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Greenwich main balance sheet or income statement drivers, such as Operating Expenses of 4.1 M, Research and Development Expense of 3.1 M or Selling General and Administrative Expense of 992.8 K, as well as many exotic indicators such as Book Value per Share of 2.24, Current Ratio of 76.24 or Debt to Equity Ratio of 0.0151. Greenwich financial statements analysis is a perfect complement when working with Greenwich Lifesciences Valuation or Volatility modules. It can also supplement various Greenwich Lifesciences Technical models . Please check the analysis of Greenwich Lifesciences Correlation against competitors.

Greenwich Lifesciences Quarterly Book Value per Share

1.494

Greenwich Book Value per Share Breakdown

Showing smoothed Book Value per Share of Greenwich Lifesciences with missing and latest data points interpolated. Measures the ratio between Shareholders Equity and [SharesWA] as adjusted by [ShareFactor].Greenwich Lifesciences' Book Value per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Greenwich Lifesciences' overall financial position and show how it may be relating to other accounts over time.
Book Value per Share10 Years Trend
Increasing
Slightly volatile
   Book Value per Share   
Share
       Timeline  

Greenwich Book Value per Share Regression Statistics

Arithmetic Mean(34.00)
Geometric Mean 17.58
Coefficient Of Variation(72.80)
Mean Deviation 21.94
Median(49.85)
Standard Deviation 24.76
Sample Variance 612.86
Range 52.76
R-Value 0.80
Mean Square Error 235.63
R-Squared 0.65
Significance 0.00090771
Slope 5.12
Total Sum of Squares 7,354

Greenwich Book Value per Share History

2019 -0.6
2020 2.91
2021 2.07
2022 2.24

Other Fundumenentals of Greenwich Lifesciences

Greenwich Lifesciences Book Value per Share component correlations

About Greenwich Lifesciences Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Greenwich Lifesciences income statement, its balance sheet, and the statement of cash flows. Greenwich Lifesciences investors use historical funamental indicators, such as Greenwich Lifesciences's Book Value per Share, to determine how well the company is positioned to perform in the future. Although Greenwich Lifesciences investors may use each financial statement separately, they are all related. The changes in Greenwich Lifesciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Greenwich Lifesciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Greenwich Lifesciences Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Greenwich Lifesciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Book Value per Share 2.07  2.24 
Tangible Assets Book Value per Share 2.10  1.91 
Enterprise Value290.4 M305.1 M
Tangible Asset Value27.2 M22.4 M
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Greenwich Lifesciences Investors Sentiment

The influence of Greenwich Lifesciences' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Greenwich. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to Greenwich Lifesciences' public news can be used to forecast risks associated with investment in Greenwich. The trend in average sentiment can be used to explain how an investor holding Greenwich can time the market purely based on public headlines and social activities around Greenwich Lifesciences. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Greenwich Lifesciences' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Greenwich Lifesciences' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Greenwich Lifesciences' news discussions. The higher the estimate score, the more favorable is the investor's outlook on Greenwich Lifesciences.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Greenwich Lifesciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Greenwich Lifesciences' short interest history, or implied volatility extrapolated from Greenwich Lifesciences options trading.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Greenwich Lifesciences using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check the analysis of Greenwich Lifesciences Correlation against competitors. Note that the Greenwich Lifesciences information on this page should be used as a complementary analysis to other Greenwich Lifesciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Complementary Tools for Greenwich Stock analysis

When running Greenwich Lifesciences price analysis, check to measure Greenwich Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Greenwich Lifesciences is operating at the current time. Most of Greenwich Lifesciences' value examination focuses on studying past and present price action to predict the probability of Greenwich Lifesciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Greenwich Lifesciences' price. Additionally, you may evaluate how the addition of Greenwich Lifesciences to your portfolios can decrease your overall portfolio volatility.
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Is Greenwich Lifesciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Greenwich Lifesciences. If investors know Greenwich will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
121.7 M
Return On Assets
-0.15
Return On Equity
-0.24
The market value of Greenwich Lifesciences is measured differently than its book value, which is the value of Greenwich that is recorded on the company's balance sheet. Investors also form their own opinion of Greenwich Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Greenwich Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Greenwich Lifesciences' market value can be influenced by many factors that don't directly affect Greenwich Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Greenwich Lifesciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Greenwich Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.